MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 01-24-2026
Insulet Corporation Total Assets 2011-2026 | PODD
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Insulet Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.09 B | 2.59 B | 2.25 B | 2.05 B | 1.87 B | 1.14 B | 929 M | 817 M | 457 M | 275 M | 302 M | 288 M | 198 M | 210 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.09 B | 198 M | 1.18 B |
Quarterly Total Assets Insulet Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.03 B | 3.47 B | 3.52 B | 3.09 B | 3.03 B | 2.88 B | 2.62 B | 2.59 B | 2.47 B | 2.39 B | 2.29 B | 2.25 B | 2.17 B | 2.11 B | 2.07 B | 2.05 B | 2 B | 1.92 B | 1.84 B | 1.87 B | 1.71 B | 1.63 B | 1.11 B | 1.14 B | 1.14 B | 1.14 B | 1.14 B | 929 M | 929 M | 929 M | 929 M | 817 M | 817 M | 817 M | 817 M | 457 M | 457 M | 457 M | 457 M | 275 M | 275 M | 275 M | 275 M | 297 M | 302 M | 302 M | 302 M | 288 M | 288 M | 288 M | 288 M | 198 M | 198 M | 198 M | 198 M | 221 M | 221 M | 221 M | 221 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.52 B | 198 M | 1.23 B |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M |  USA |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | USA |
 |
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | USA |
 |
Aziyo Biologics
AZYO
|
43.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Apyx Medical Corporation
APYX
|
79.2 M | $ 3.88 | -1.02 % | $ 134 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
498 M | $ 6.9 | -4.17 % | $ 495 M |  Israel |
 |
Alphatec Holdings
ATEC
|
776 M | $ 13.17 | -2.23 % | $ 1.88 B | USA |
 |
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | USA |
 |
Bio-Rad Laboratories
BIO
|
9.36 B | $ 292.08 | -0.55 % | $ 8.24 B | USA |
 |
Bruker Corporation
BRKR
|
5.81 B | $ 36.61 | -13.72 % | $ 5.46 K | USA |
 |
BioSig Technologies
BSGM
|
842 K | - | 37.08 % | $ 85.7 M | USA |
 |
CONMED Corporation
CNMD
|
2.31 B | $ 41.57 | -1.8 % | $ 1.28 B | USA |
 |
Boston Scientific Corporation
BSX
|
39.4 B | $ 74.23 | 1.03 % | $ 109 B | USA |
 |
Abbott Laboratories
ABT
|
81.4 B | $ 112.24 | -1.19 % | $ 195 B | USA |
 |
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | USA |
 |
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | USA |
 |
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | USA |
 |
ClearPoint Neuro
CLPT
|
39.2 M | $ 13.0 | -2.8 % | $ 351 M | USA |
 |
EDAP TMS S.A.
EDAP
|
86.1 M | $ 4.82 | -1.73 % | $ 180 M |  France |
 |
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | USA |
 |
Electromed
ELMD
|
53.8 M | $ 23.39 | -7.4 % | $ 198 M | USA |
 |
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M |  Canada |
 |
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | USA |
 |
Eargo
EAR
|
132 M | - | - | $ 10.2 M | USA |
 |
InMode Ltd.
INMD
|
786 M | $ 14.36 | 0.81 % | $ 1.14 B | Israel |
 |
Second Sight Medical Products
EYES
|
41.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
IRadimed Corporation
IRMD
|
98.3 M | $ 99.45 | -3.52 % | $ 1.26 B | USA |
 |
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | USA |
 |
FONAR Corporation
FONR
|
199 M | $ 18.54 | -0.22 % | $ 122 M | USA |
 |
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | USA |
 |
Integer Holdings Corporation
ITGR
|
3.08 B | $ 84.9 | -2.62 % | $ 2.85 B | USA |
 |
Globus Medical
GMED
|
5.25 B | $ 87.0 | -1.43 % | $ 11.8 B | USA |
 |
Pulmonx Corporation
LUNG
|
163 M | $ 1.44 | -1.03 % | $ 56.3 M | USA |
 |
Myomo
MYO
|
10.2 M | $ 0.8 | 0.29 % | $ 5.64 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
4.04 B | $ 10.88 | -2.68 % | $ 838 M | USA |
 |
Establishment Labs Holdings
ESTA
|
347 M | $ 72.93 | 0.29 % | $ 2.05 B |  Costa-rica |
 |
Medigus Ltd.
MDGS
|
37.5 M | - | 10.28 % | $ 55.5 M | Israel |
 |
IRIDEX Corporation
IRIX
|
34.4 M | $ 1.35 | -5.59 % | $ 21.8 M | USA |
 |
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | USA |
 |
Cytosorbents Corporation
CTSO
|
47.4 M | $ 0.63 | 1.76 % | $ 34.3 M | USA |